Key result
Fenfluramine is linked to reversible prothrombin time shortening and abnormal fibrin structure.
Why the study?
Clotting abnormalities associated with fenfluramine use had not been previously reported despite its clinical use and known adverse effects.
Case Report (n=1)
This first report of clotting abnormalities associated with fenfluramine use suggests it may induce rapid clot formation and abnormal fibrin structure, potentially increasing thrombotic risk.
Answers are grounded in this paper and cite their sources.
Fenfluramine may promote abnormal fibrin and hypercoagulability; single case leaves open thrombotic risk and need for confirmation.
A 35-year-old woman experienced symptomatic calf pain while taking a combination of fenfluramine and phentermine. All symptoms resolved when the medications were stopped, but pain returned when fenfluramine was restarted. Laboratory evaluation revealed mild elevations of aspartate aminotransferase and lactate dehydrogenase and a remarkably shortened prothrombin time (6.3 seconds). Additional studies revealed that the clots were composed of very thin fibrin fibers. All laboratory abnormalities, including the abnormal fibrin structure, completely resolved when fenfluramin was stopped. Direct addition of fenfluramine or phentermine to normal plasma did not alter either coagulation kinetics or fibrin structure, supporting the concept that the induced changes may have originated at the hepatic level. Clots composed of thin fibers are much more resistant to fibrinolysis, and could potentially put such patients at risk for thrombotic complications. This is the first report of clotting abnormalities associated with fenfluramine use. Subsequent to its use in this patient, fenfluramine was removed from clinical use due to reports of acquired valvular heart disease.
No takes yet. Share an insight, caveat, or question.
Carr et al. (2001) conducted a case report in Symptomatic calf pain and clotting abnormalities (n=1). Fenfluramine and phentermine vs. Medication cessation was evaluated on Clotting abnormalities (prothrombin time and fibrin structure). Fenfluramine use was associated with symptomatic calf pain, a shortened prothrombin time, and abnormal thin fibrin fibers that completely resolved when the medication was stopped.
Synapse has enriched 10 related papers. Consider them for comparative context: